Skip to content

Comparative Study on the Efficacy of Endoscopic Anti-Reflux Mucoplasty with Valve versus Anti-Reflux Mucosectomy in the Treatment of Gastroesophageal Reflux Disease

Comparative Study on the Efficacy of Endoscopic Anti-Reflux Mucoplasty with Valve versus Anti-Reflux Mucosectomy in the Treatment of Gastroesophageal Reflux Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113034
Enrollment
Unknown
Registered
2025-11-24
Start date
2025-11-24
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease

Interventions

ARMS group:Endoscopic Anti-Reflux Mucosectomy (ARMS)
ARM-P/V Group:Endoscopic Anti-Reflux Mucoplasty with Valve (ARM-P/V)

Sponsors

The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Age between 18 and 75 years, diagnosed with GERD (confirmed by endoscopy, reflux monitoring, or typical symptoms responsive to acid suppressants); (2) Ineffective after taking standard or high-dose acid suppressants for more than 8 weeks, or unwilling to take long-term medication, or unable to tolerate due to drug-related adverse reactions; (3) DeMeester score > 15 in 24-hour esophageal dynamic pH monitoring, and esophageal acid exposure time (AET) (pH 6%.

Exclusion criteria

Exclusion criteria: (1) Hiatus hernia (HH) length > 2 cm; (2) Reflux esophagitis (RE) Los Angeles classification grade C or D; (3) Long-segment Barrett's esophagus; (4) Presence of esophageal dysplasia, portal hypertension and/or esophagogastric varices, esophageal stenosis, and esophageal ulcer; (5) Presence of other motility disorders and severe failure of esophageal body peristalsis assessed by preoperative manometry. (6) Severe dysfunction of vital organs (heart, liver, kidney, etc.), combined with coagulation abnormalities, combined with other systemic diseases that make it difficult to tolerate the surgery, pregnant women, etc.

Design outcomes

Primary

MeasureTime frame
Gastroesophageal Reflux Disease Health-Related Quality of Life (GERD-HRQL) questionnaire scores;

Secondary

MeasureTime frame
GERD Questionnaire (GERD-Q);reflux severity index (RSI);the 12-items Short Form Health Survey;acid suppressant dosage;Gastroesophageal flap valve morphology (endoscopic Hill classification);24-hour esophageal dynamic pH monitoring results;High-resolution esophageal manometry (HREM);

Countries

China

Contacts

Public ContactYurong Tang

The First Affiliated Hospital with Nanjing Medical University

story_tyr@163.com+86 138 1388 4275

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026